Pylobactell Den Europæiske Union - dansk - EMA (European Medicines Agency)

pylobactell

torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - diagnostiske midler - dette lægemiddel er kun til diagnostisk brug. til in vivo-diagnosticering af gastroduodenal helicobacter pylori (h. pylori) infektion.

Provocholine 100 mg pulver til opløsning til nebulisator Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

provocholine 100 mg pulver til opløsning til nebulisator

acic europe limited - methacholinchlorid - pulver til opløsning til nebulisator - 100 mg

Xaluprine (previously Mercaptopurine Nova Laboratories) Den Europæiske Union - dansk - EMA (European Medicines Agency)

xaluprine (previously mercaptopurine nova laboratories)

nova laboratories ireland limited - 6-mercaptopurinmonohydrat - leukæmi, lymfoid - antineoplastiske midler - xaluprine er indiceret til behandling af akut lymfoblastisk leukæmi (all) hos voksne, unge og børn.

Xromi Den Europæiske Union - dansk - EMA (European Medicines Agency)

xromi

nova laboratories ireland limited - hydroxycarbamid - anæmi, sickle cell - antineoplastiske midler - forebyggelse af vaso-okklusive komplikationer af seglcelleanæmi hos patienter over 2 år.

Jayempi Den Europæiske Union - dansk - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Qaialdo Den Europæiske Union - dansk - EMA (European Medicines Agency)

qaialdo

nova laboratories ireland limited - spironolacton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 og 5.

Spotinor 10 mg/ml spot-on, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

spotinor 10 mg/ml spot-on, opløsning

norbrook laboratories (ireland) limited - deltamethrin - spot-on, opløsning - 10 mg/ml - får, kvæg

Norfol 10 mg/ml injektionsvæske, emulsion Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norfol 10 mg/ml injektionsvæske, emulsion

norbrook laboratories (ireland) limited - propofol - injektionsvæske, emulsion - 10 mg/ml

Closamectin Pour-On 5 mg/ml+200 mg/ml pour-on, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

closamectin pour-on 5 mg/ml+200 mg/ml pour-on, opløsning

norbrook laboratories (ireland) limited - closantel, ivermectin - pour-on, opløsning - 5 mg/ml+200 mg/ml - kvæg